Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?

Front Public Health. 2020 May 15:8:185. doi: 10.3389/fpubh.2020.00185. eCollection 2020.

Authors

Aurélien Mary^{1

2}, Lucie Hénaut², Jean-Luc Schmit^{3

4}, Jean-Philippe Lanoix^{3

4}, Michel Brazier^{2

5}

Affiliations

¹ Clinical Critical Care Pharmacy Department, Amiens-Picardie University Hospital, Amiens, France.
² UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France.
³ Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France.
⁴ AGIR UR UPJV 4294, CURS, University of Picardie Jules Verne, Amiens, France.
⁵ Department of Biochemistry, Amiens-Picardie University Hospital, Amiens, France.

No abstract available

Keywords: COVID-19; SARS-CoV-2; azithromycin; hydroxychloroquine; type I interferon.

MeSH terms

Antimalarials / therapeutic use
COVID-19 / therapy*
Humans
Hydroxychloroquine / administration & dosage
Interferon Type I / administration & dosage*
Nebulizers and Vaporizers*
SARS-CoV-2 / isolation & purification

Substances

Antimalarials
Interferon Type I
Hydroxychloroquine